AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16094780 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) in Group 2 (Patients with upper limb spasticity)
Number of subjects: 21
Study 16094780 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) in Group 3 (Lower limb spasticity patients)
Number of subjects: 21
Study 12392805 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly cognitive behavioral therapy sessions
Number of subjects: 68
Study 12392805 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly cognitive behavioral therapy sessions
Number of subjects: 68
Study 12392805 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly cognitive behavioral therapy sessions
Number of subjects: 68
Study 10580197 — intervention group
Group type: EXPERIMENTAL
Intervention: Canarypox virus vaccine (vCP300)
Number of subjects: 23
Study 10580197 — intervention group
Group type: COMPARATOR
Intervention: Control injections
Number of subjects: 23
Study 7593700 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon membrane and fibrin glue
Number of subjects: 11
Study 7593700 — intervention group
Group type: COMPARATOR
Intervention: Teflon membrane alone
Number of subjects: 11
Study 2206824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciba-Geigy carbamazepine preparation
Number of subjects: 23
Study 2206824 — intervention group
Group type: COMPARATOR
Intervention: Ethical Generics carbamazepine preparation
Number of subjects: 23
Study 6157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 0
Study 6157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 6157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ouabain
Number of subjects: 0
Study 6157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 31525120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention group
Number of subjects: 4500
Study 31525120 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet on healthy nutrition)
Number of subjects: 4500
Study 29781243 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements containing Bifidobacterium and Lactobacillus
Number of subjects: 57
Study 29781243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 28544702 — intervention group
Group type: EXPERIMENTAL
Intervention: C15:0 blood levels
Number of subjects: 0
Study 28544702 — intervention group
Group type: EXPERIMENTAL
Intervention: C17:0 blood levels
Number of subjects: 0
Study 28544702 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in dairy intake (total dairy, high-fat dairy, cheese, butter)
Number of subjects: 0
Study 28544702 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in high-fat dairy and cream intake
Number of subjects: 0
Study 26463717 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 273
Study 26463717 — intervention group
Group type: COMPARATOR
Intervention: Open rotator cuff repair
Number of subjects: 273
Study 24060193 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP (4-session, 15-hr small-group intervention)
Number of subjects: 174
Study 24060193 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE (4-session, 15-hr small-group intervention)
Number of subjects: 174
Study 24060193 — intervention group
Group type: EXPERIMENTAL
Intervention: RA (1-session relationship awareness intervention)
Number of subjects: 174
Study 24060193 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 174
Study 24060193 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP
Number of subjects: 174
Study 24060193 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE
Number of subjects: 174
Study 21130513 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitor PF-734200 (multiple doses for 28 days)
Number of subjects: 72
Study 21130513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 72
Study 19608530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19608530 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily
Number of subjects: 45
Study 19608530 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg once daily and Aspirin 350 mg twice daily
Number of subjects: 45
Study 17553909 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) plus non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 17553909 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 0
Study 15066879 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Development Curriculum (SDC)
Number of subjects: 0
Study 15066879 — intervention group
Group type: EXPERIMENTAL
Intervention: School/Community Intervention (SCI)
Number of subjects: 0
Study 15066879 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo Health Enhancement Curriculum (HEC)
Number of subjects: 0
Study 11570939 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-knee stocking (20-30 mm Hg)
Number of subjects: 202
Study 11570939 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stocking (30-40 mm Hg)
Number of subjects: 202
Study 11570939 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 202
Study 9863994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air exercise (‐10 degrees C)
Number of subjects: 8
Study 9863994 — intervention group
Group type: COMPARATOR
Intervention: Temperate air exercise (22 degrees C)
Number of subjects: 8
Study 8165192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (microemulsion formulation)
Number of subjects: 48
Study 8165192 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (commercial formulation)
Number of subjects: 48
Study 8165192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral
Number of subjects: 48
Study 3503451 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental phenolization
Number of subjects: 156
Study 3503451 — intervention group
Group type: COMPARATOR
Intervention: Wedge excision
Number of subjects: 156
Study 31297890 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants given formula supplements
Number of subjects: 110
Study 31297890 — intervention group
Group type: COMPARATOR
Intervention: Exclusively formula-fed infants
Number of subjects: 110
Study 29354913 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular plaster therapy
Number of subjects: 34
Study 29354913 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 34
Study 25299350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release tramadol HCl 75 mg/acetaminophen 650 mg (TA-ER)
Number of subjects: 320
Study 25299350 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tramadol HCl 37.5 mg/acetaminophen 325 mg (TA-IR)
Number of subjects: 320
Study 23958154 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program consisting of six group sessions and an ehealth module
Number of subjects: 142
Study 23958154 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142
Study 21426839 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 63
Study 21426839 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 63
Study 21426839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 63
Study 21426839 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost, Travoprost, Bimatoprost
Number of subjects: 63
Study 18978388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam for posterior restorations
Number of subjects: 66
Study 18978388 — intervention group
Group type: COMPARATOR
Intervention: Resin-based composite restorations
Number of subjects: 66
Study 15979735 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg i.v. dexamethasone preoperatively
Number of subjects: 62
Study 15979735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12838354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders from General Practitioners (GP)
Number of subjects: 109
Study 12838354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders from Hospitals
Number of subjects: 109
Study 12838354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone reminders)
Number of subjects: 109
Study 12838354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined telephone-reminded group (GP + Hospital)
Number of subjects: 109
Study 10954376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional filters (BF) applied to 340 patients
Number of subjects: 598
Study 10954376 — intervention group
Group type: COMPARATOR
Intervention: Spectral filters (SF) applied to 258 patients
Number of subjects: 598
Study 8727868 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (Plendil) 10 mg
Number of subjects: 27
Study 8727868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2050168 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 75
Study 2050168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 6841933 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time employment (20 hours per week)
Number of subjects: 55
Study 6841933 — intervention group
Group type: COMPARATOR
Intervention: Control (no part-time employment)
Number of subjects: 55
Study 30760311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-maintained propofol sedation (PMPS)
Number of subjects: 2
Study 30760311 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetist-controlled propofol sedation (ACPS)
Number of subjects: 2
Study 28418835 — intervention group
Group type: EXPERIMENTAL
Intervention: DT2 treatment
Number of subjects: 0
Study 28418835 — intervention group
Group type: EXPERIMENTAL
Intervention: CMP4 treatment
Number of subjects: 0
Study 28418835 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinent Contingent Housing (ACH3)
Number of subjects: 0
Study 28418835 — intervention group
Group type: COMPARATOR
Intervention: Base Case
Number of subjects: 0
Study 25377788 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage dose protocol (group 1)
Number of subjects: 51
Study 25377788 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose protocol (group 2)
Number of subjects: 51
Study 25377788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference transport modality
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling cart transport modality
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack transport modality
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder strap transport modality
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-overweight group
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group
Number of subjects: 0
Study 24370761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 0
Study 22186814 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit endodontic therapy
Number of subjects: 32
Study 22186814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-visit endodontic therapy
Number of subjects: 32
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (questionnaire and additional explanation)
Number of subjects: 164
Study 20051190 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal and written instructions)
Number of subjects: 164
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary instructions (liquid vs solid food consumed)
Number of subjects: 164
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since last solid meal
Number of subjects: 164
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Elapsed time to first bowel movement from initiation of bowel preparation
Number of subjects: 164
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 55
Number of subjects: 164
Study 20051190 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate bowel preparation
Number of subjects: 164
Study 17725757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation of accessory pathways
Number of subjects: 39
Study 15199366 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 92
Study 15199366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 11383595 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5, 10, or 20 mg/kg body weight)
Number of subjects: 11
Study 11383595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11383595 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11
Study 9923056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal levocabastine
Number of subjects: 0
Study 9923056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8055605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 39
Study 8055605 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 39
Study 8055605 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 39
Study 8055605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bupivacaine groups
Number of subjects: 39
Study 8055605 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 0.25% bupivacaine
Number of subjects: 39
Study 2787155 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanal electrical stimulation at the promontory
Number of subjects: 462
Study 2787155 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine
Number of subjects: 462
Study 2787155 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 462
Study 2787155 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking by hearing aids or tinnitus maskers
Number of subjects: 462
Study 4456575 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarin prophylaxis
Number of subjects: 14
Study 4456575 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 14
Study 4456575 — intervention group
Group type: COMPARATOR
Intervention: Small doses of heparin
Number of subjects: 14
Study 31005374 — intervention group
Group type: EXPERIMENTAL
Intervention: GPCATGA+/TMA+AG patients
Number of subjects: 304
Study 28202475 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (50 g) added to standard white-bread challenge
Number of subjects: 22
Study 28202475 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (50 g) added to standard white-bread challenge
Number of subjects: 22
Study 28202475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (11.1 g) added to standard white-bread challenge
Number of subjects: 22
Study 28202475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber (4.8 or 9.6 g) added to standard white-bread challenge
Number of subjects: 22
Study 26415035 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (1 mg/kg/day) for six months
Number of subjects: 45
Study 26415035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23850467 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended tones
Number of subjects: 0
Study 23850467 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended tones
Number of subjects: 0
Study 23850467 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent tones
Number of subjects: 0
Study 23850467 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent tones
Number of subjects: 0
Study 21547406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic frequency diastolic vibro‐percussion (50 Hz, 2 mm amplitude) applied upon the rib‐spaces of the left sternal border
Number of subjects: 90
Study 21547406 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Inter-Costal Space (ICS) proximate the left sternal border
Number of subjects: 90
Study 21547406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth Inter-Costal Space (ICS) proximate the left sternal border
Number of subjects: 90
Study 21547406 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Inter-Costal Space (ICS) right sternal border
Number of subjects: 90
Study 21547406 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth Inter-Costal Space (ICS) right sternal border
Number of subjects: 90
Study 17426747 — intervention group
Group type: EXPERIMENTAL
Intervention: Various staple carbohydrate-rich foods (33 foods including breads, breakfast cereals, pasta, rice, and potatoes)
Number of subjects: 42
Study 17426747 — intervention group
Group type: COMPARATOR
Intervention: Glucose (25 or 50 g portions)
Number of subjects: 42
Study 16402242 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg)
Number of subjects: 18
Study 16402242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 18
Study 16402242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (40 mg)
Number of subjects: 18
Study 12926337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 200
Study 12926337 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OG)
Number of subjects: 200
Study 10715293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1.5 g orally every 6 hours)
Number of subjects: 123
Study 10715293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 10715293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 123
Study 9363870 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR dot-blot analysis for CEA mRNA
Number of subjects: 24
Study 1586618 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, doxorubicin 50 mg/m2, prednisone 50 mg/m2)
Number of subjects: 89
Study 1586618 — intervention group
Group type: COMPARATOR
Intervention: CNOP (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, mitoxantrone 10 mg/m2, prednisone 50 mg/m2)
Number of subjects: 89
Study 1586618 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 89
Study 1586618 — intervention group
Group type: COMPARATOR
Intervention: CNOP
Number of subjects: 89
Study 3839679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 3839679 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 3839679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31704907 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI (n=92)
Number of subjects: 153
Study 31704907 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI for 19DEL mutant NSCLC
Number of subjects: 153
Study 31704907 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI for L858 mutant NSCLC
Number of subjects: 153
Study 31704907 — intervention group
Group type: COMPARATOR
Intervention: Single EGFR-TKI (n=61)
Number of subjects: 153
Study 31704907 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine combining EGFR-TKI
Number of subjects: 153
Study 29310138 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, moderate-intensity physical activity program
Number of subjects: 1635
Study 29310138 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1635
Study 29310138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1635
Study 27154810 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for two weeks
Number of subjects: 46
Study 27154810 — intervention group
Group type: COMPARATOR
Intervention: Normal diet for two weeks
Number of subjects: 46
Study 24669010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC)
Number of subjects: 130
Study 24669010 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy alone (RC)
Number of subjects: 130
Study 22986565 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session walk-in counselling services
Number of subjects: 0
Study 19573727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue percutaneous coronary intervention (R-PCI)
Number of subjects: 427
Study 19573727 — intervention group
Group type: COMPARATOR
Intervention: Repeat thrombolysis
Number of subjects: 427
Study 19573727 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 427
Study 19573727 — intervention group
Group type: EXPERIMENTAL
Intervention: R-PCI
Number of subjects: 427
Study 17288699 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER) 1000 mg once daily for 5 days
Number of subjects: 818
Study 17288699 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days or telithromycin 800 mg once daily for 5 days (comparator)
Number of subjects: 818
Study 16091224 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 16091224 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized choice of initial ART regimen
Number of subjects: 0
Study 12494803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (n = 22), 10 mg/h during 2 h then 5 mg every 4 h
Number of subjects: 44
Study 12494803 — intervention group
Group type: COMPARATOR
Intervention: Nebulized adrenaline (n = 22), 6 mg/h during 2 h then 3 mg every 4 h
Number of subjects: 44
Study 9829018 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil
Number of subjects: 451
Study 9829018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 9829018 — intervention group
Group type: COMPARATOR
Intervention: Active controls
Number of subjects: 451